Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment
27/5 07:24
(RTTNews) - Sanofi - Aventis Groupe said that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa or isatuximab in combination with bortezomib, lenalidomide and dexame...